Analysing the Effect of Empagliflozin on Reduction of Tissue Sodium Content in Patients With Chronic Heart Failure

PHASE2CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

July 1, 2017

Primary Completion Date

January 31, 2020

Study Completion Date

April 30, 2020

Conditions
Chronic Heart Failure
Interventions
DRUG

Empagliflozin 10mg

"Each patient, after the run-in/wash-out phase, will be randomly assigned in a doubleblind fashion to one of the two treatment sequences according to a randomisation list.~and provided by the sponsor."

DRUG

Placebo Oral Tablet

"Each patient, after the run-in/wash-out phase, will be randomly assigned in a doubleblind fashion to one of the two treatment sequences according to a randomisation list.~and provided by the sponsor."

Trial Locations (1)

91054

Clinical Research Center, Department of Nephrology and Hypertension, University of Erlangen-Nuremberg, Erlangen

All Listed Sponsors
lead

University of Erlangen-Nürnberg Medical School

OTHER

NCT03128528 - Analysing the Effect of Empagliflozin on Reduction of Tissue Sodium Content in Patients With Chronic Heart Failure | Biotech Hunter | Biotech Hunter